EUCTR2006-000247-26-DE进行中（未招募）不适用
A Phase 3, Open-Label, Three-Group Parallel Study to Evaluate the Efficacy and Safety of Human Insulin Inhalation Powder (HIIP) in Patients with Type 2 Diabetes Treated with Once-Daily Insulin Glargine - IDBA
Eli Lilly and Company Ltd0 个研究点目标入组 510 人开始时间: 2006年3月29日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 510
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients are eligible to be included in the study only if they meet all of the following criteria at screening or otherwise as described below:
- •[1] Are male or female who are 18 years of age or older,
- •[2] Have had type 2 diabetes mellitus for at least 6 months’ duration at study entry,
- •[3] Have been treated with the following regimen: one or more oral anti-hyperglycemic medications on a stable dose for at least 6 weeks (3 months for thiazolidinediones [TZDs]) AND once-daily insulin glargine for at least 4 months
- •[4] Have HbA1c =7.5 and =10.5% at screening
- •[5] If female, are not breastfeeding
- •If female and of childbearing potential must
- •test negative for pregnancy at the time of screening
- •intend not to become pregnant during the study,
- •agree to use a reliable method of birth control
- •[6] Are nonsmokers, have not smoked for at least 6 months prior to entering the study, and agree not to smoke. Serum cotinine
- •level must be <20 ng/mL at screening.
- •[7] Are able to perform pulmonary function testing,
- •[8] Have PFTs graded as A,” B,” or C” in quality
- •[9] Have a chest x-ray without evidence of clinically significant pulmonary abnormalities
- •[10] Have signed and dated the informed consent document.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients will be excluded from the study if they meet any of the following criteria:
- •[1] Are investigative site personnel directly affiliated with the study, and/or their immediate families.
- •[2] Are Lilly or Alkermes employees
- •[3] Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry
- •[4] Patients who have previously completed or withdrawn from this study or any study investigating any form of inhaled insulin and took one or more doses of inhaled insulin, or have previously taken any form of inhaled insulin
- •[5] Are taking a TZD dose greater than what is indicated in combination with insulin according to the TZD label in the respective country (for example, in the United States, rosiglitazone greater than 4 mg daily or pioglitazone greater than 45 mg daily is not currently indicated). In countries where the combination of the TZD and insulin is not approved, patients taking any TZD at study entry will be excluded.
- •[6] Have had more than two episodes of severe hypoglycemia during the 6 months prior to study entry
- •[7] Have had more than one hospitalization or emergency room visit due to poor diabetic control during the 6 months prior to study entry,
- •[8] Have had a lower respiratory infection in the 3 months prior to screening, evidenced by diagnosed pneumonia
- •[9] Have received systemic glucocorticoid therapy within the 3 months prior to study entry (topical preparations, nasal preparations, intra-articular administration, as well as physiologic replacement for Addison’s Disease and hypopituitarism are permitted),
- •[10] Have obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis, or alanine aminotransaminase/serum glutamic pyruvic transaminase (ALT/SGPT) greater than three times the upper limit of the reference range,
- •[11] Have a history of renal transplantation, are currently receiving renal dialysis, or have a serum creatinine >2.0 mg/dL (177 µmol/L) if not on metformin; or if on metformin at study entry, have a serum creatinine above what is contraindicated in the metformin label in the respective country
- •[12] Have a history of angina, myocardial infarction, or Functional Capacity Class III/IV cardiac disease within the 6 months prior to study entry,
- •[13] Have an active or untreated malignancy, or have been in remission from a clinically significant malignancy for less than 5 years
- •[14] Have a current or past history of lung cancer
- •[15] Have a history of lung transplantation
- •[16] Have a current diagnosis or past history of asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, bronchiectasis, alpha-1 antitrypsin deficiency, or other clinically relevant pulmonary disease that, in the opinion of the investigator, would preclude participation in the study due to safety concerns, or confound data interpretation,
- •[17] Are taking or have taken exenatide (Byetta™) within 6 weeks,
- •[18] Require more than 150 U/day of insulin glargine,
- •[19] Have any other condition (including reported drug abuse, alcohol abuse, or psychiatric disorder) that, in the opinion of the investigator, precludes the patient from following and completing the protocol,
- •[20] Fail to satisfy the investigator of suitability to participate for any other reason.
研究者
相似试验
进行中（未招募）
不适用
A Phase 3, Open-Label, Three-Group Parallel Study to Evaluate the Efficacy and Safety of Human Insulin Inhalation Powder (HIIP) in Patients with Type 2 Diabetes Treated with Once-Daily Insulin Glargine - IDBAEUCTR2006-000247-26-GBEli Lilly and Company Ltd510
进行中（未招募）
不适用
A Phase 3, Open-Label, Parallel-Group Study to Compare Two Dosing Algorithms for Preprandial Human Insulin Inhalation Powder (HIIP) in Insulin-Naïve Patientswith Type 2 Diabetes Mellitus - IDAYMale or non pregnant female nonsmoking patients, 18 years of age or older: have had type 2 diabetes mellitus for at least 6 months, and have been treated with one or more oral antihyperglycemic medications for at least 6 weeks (12 weeks for thiazolidinediones [TZDs]), and are insulin-naïve as defined in the protocol, have HbA1c >7.0% and =10.5%, and FEV1 and DLCO >70% of predicted valueMedDRA version: 8.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusEUCTR2006-002999-17-BEEli Lilly and Company Limited360
进行中（未招募）
不适用
A Phase 3, Open-Label, Parallel-Group Study to Compare Two Dosing Algorithms for Preprandial Human Insulin Inhalation Powder (HIIP) in Insulin-Naïve Patientswith Type 2 Diabetes Mellitus - IDAYMale or non pregnant female nonsmoking patients, 18 years of age or older: have had type 2 diabetes mellitus for at least 6 months, and have been treated with one or more oral antihyperglycemic medications for at least 6 weeks (12 weeks for thiazolidinediones [TZDs]), and are insulin-naïve as defined in the protocol, have HbA1c >7.0% and =10.5%, and FEV1 and DLCO >70% of predicted valueMedDRA version: 8.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusEUCTR2006-002999-17-ATEli Lilly and Company Limited360
未知
3 期
A phase 3, open-label, parallel-group study to evaluate the dosing regimens of human lymphoblastoid interferon (HLBI) in hepatitis C patients with compensated cirrhosis.Chronic hepatitis C with compensated cirrhosisJPRN-jRCT2080220087Dainippon Sumitomo Pharma Co., Ltd.
招募中
3 期
Phase 3 Study of Gedatolisib in HR-Positive, HER2-Negative Advanced Breast Cancer Patients (VIKTORIA-1)CTRI/2023/08/056738PSI CRO Pharma India Pvt Ltd